Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers

被引:51
|
作者
Carlson J.J. [1 ]
Gries K.S. [1 ]
Yeung K. [1 ]
Sullivan S.D. [1 ]
Garrison Jr. L.P. [1 ]
机构
[1] Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195-7630
关键词
National Health Service; Health Technology Assessment; Administrative Burden; Conditional Coverage; Pharmaceutical Benefit Advisory Committee;
D O I
10.1007/s40258-014-0093-x
中图分类号
学科分类号
摘要
Our objective was to identify and characterize publicly available cases and related trends for performance-based risk-sharing arrangements (PBRSAs). We performed a review of PBRSAs over the past 20 years (1993-2013) using available databases and reports from colleagues and healthcare experts. These were categorized according to a previously published taxonomy of scheme types and assessed in terms of the underlying product and market attributes for each scheme. Macro-level trends were identified related to the timing of scheme adoption, countries involved, types of arrangements, and product and market factors. Our search yielded 148 arrangements. From this set, 65 arrangements included a coverage with an evidence development component, 20 included a conditional treatment continuation component, 54 included a performance-linked reimbursement component, and 42 included a financial utilization component. Each type of scheme addresses fundamental uncertainties that exist when products enter the market. The pace of adoption appears to be slowing, but new countries continue to implement PBRSAs. Over this 20-year period, there has been a consistent movement toward arrangements that minimize administrative burden. In conclusion, the pace of PBRSA adoption appears to be slowing but still has traction in many health systems. These remain a viable coverage and reimbursement mechanism for a wide range of medical products. The long-term viability and growth of these arrangements will rest in the ability of the parties to develop mutually beneficial arrangements that entail minimal administrative burden in their development and implementation. © 2014 Springer International Publishing.
引用
收藏
页码:231 / 238
页数:7
相关论文
共 37 条
  • [1] Comment on: "Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers"
    Curto, Alessandro
    Garattini, Livio
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2014, 12 (05) : 565 - 565
  • [2] Comment on: “Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers”
    Alessandro Curto
    Livio Garattini
    Applied Health Economics and Health Policy, 2014, 12 (5) : 565 - 565
  • [3] Authors’ Reply to Curto and Garattini: “Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers”
    Josh J. Carlson
    Katie Gries
    Kai Yeung
    Sean D. Sullivan
    Louis P. Garrison
    Applied Health Economics and Health Policy, 2014, 12 (5) : 567 - 568
  • [4] Authors' Reply to Curto and Garattini: "Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers"
    Carlson, Josh J.
    Gries, Katie
    Yeung, Kai
    Sullivan, Sean D.
    Garrison, Louis P.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2014, 12 (05) : 567 - 568
  • [5] CURRENT STATUS AND TRENDS IN PERFORMANCE-BASED SCHEMES BETWEEN HEALTH CARE PAYERS AND MANUFACTURERS
    Carlson, J. J.
    Gries, K.
    Sullivan, S. D.
    Garrison, L.
    VALUE IN HEALTH, 2011, 14 (07) : A359 - A360
  • [6] Performance-Based Risk-Sharing Arrangements: An Updated International Review
    Carlson, Josh J.
    Chen, Shuxian
    Garrison, Louis P., Jr.
    PHARMACOECONOMICS, 2017, 35 (10) : 1063 - 1072
  • [7] Emerging roles for pharmacists in performance-based risk-sharing arrangements
    Calabrese, Martin J.
    Cooke, Catherine E.
    Watson, Kristin
    de Bittner, Magaly Rodriguez
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2017, 74 (13) : 1007 - 1012
  • [8] Performance-Based Risk-Sharing Arrangements: An Updated International Review
    Josh J. Carlson
    Shuxian Chen
    Louis P. Garrison
    PharmacoEconomics, 2017, 35 : 1063 - 1072
  • [9] PERFORMANCE-BASED RISK-SHARING ARRANGEMENTS IN DIAGNOSTICS AND DEVICES IN THE UNITED STATES
    Chen, Y.
    Carlson, J.
    VALUE IN HEALTH, 2021, 24 : S238 - S238
  • [10] When do performance-based risk-sharing arrangements make sense?
    Drummond, Michael
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2015, 16 (06): : 569 - 571